Usefulness of Everolimus-Eluting Coronary Stent Implantation in Patients on Maintenance Hemodialysis

被引:14
|
作者
Ikari, Yuji [1 ]
Kyono, Hiroyuki [2 ]
Isshiki, Takaaki [2 ]
Ishizuka, Shuichi [3 ]
Nasu, Kenya [3 ]
Sano, Koichi [4 ]
Okada, Hisayuki [5 ]
Sugano, Teruyasu [6 ]
Uehara, Yoshiki [7 ]
机构
[1] Tokai Univ, Sch Med, Dept Cardiovasc Med, Isehara, Kanagawa 25911, Japan
[2] Teikyo Univ Hosp, Tokyo, Japan
[3] Toyohashi Heart Ctr, Toyohashi, Aichi, Japan
[4] Iwatsuki Minami Hosp, Iwatsuki, Saitama, Japan
[5] Seirei Hamamatsu Gen Hosp, Hamamatsu, Shizuoka, Japan
[6] Yokohama City Univ Med, Yokohama, Kanagawa, Japan
[7] Mito Brain Heart Ctr, Mito, Ibaraki, Japan
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2015年 / 116卷 / 06期
关键词
ACUTE MYOCARDIAL-INFARCTION; LONG-TERM SURVIVAL; BARE-METAL STENTS; DIALYSIS PATIENTS; UNITED-STATES; CYPHER STENT; REVASCULARIZATION; THROMBOSIS;
D O I
10.1016/j.amjcard.2015.05.061
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The outcomes of second-generation drug-eluting stent (DES) are unknown in patients on maintenance hemodialysis (HD) although HD has been reported as a strong predictor of adverse outcome after the first-generation DES implantation. The OUCH-PRO Study is a prospective multicenter single-arm registry design to study clinical and angiographic outcomes after everolimus-eluting stent (EES). Patients who underwent maintenance HD were prospectively enrolled at the time of elective coronary intervention using EES. Quantitative coronary angiography was performed in an independent core laboratory. The primary end point was the occurrence of target vessel failure (TVF) defined as cardiac death, myocardial infarction (MI), and target vessel revascularization at 1 year. A total of 123 patients were enrolled and 161 EES were implanted. The TVF rate at 1 year was 18% (4% cardiac death, 0% MI, 17% target vessel revascularization). No stent thrombosis was documented. Other clinical events at 1 year were 3% noncardiac death, 3% stroke, and 9% non-target-vessel revascularization. Late lumen loss in stent was 0.37 +/- 0.63 mm at 8 months. In conclusion, EES had a high TVF rate and great late lumen loss in patients on BED compared with previous huge EES data in non-HD patients. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:872 / 876
页数:5
相关论文
共 50 条
  • [1] Coronary vasomotion dysfunction after everolimus-eluting stent implantation
    Giudice, Pietro
    Attisano, Tiziana
    Di Maio, Marco
    Bellino, Elisabetta M.
    Polito, Maria V.
    Baldi, Cesare
    Vigorito, Francesco
    Di Muro, Michele R.
    Tomasello, Salvatore D.
    Galassi, Alfredo R.
    Piscione, Federico
    [J]. INTERVENTIONAL MEDICINE AND APPLIED SCIENCE, 2014, 6 (04): : 178 - 182
  • [2] Sirolimus-Eluting Stent vs. Everolimus-Eluting Stent for Coronary Intervention in Patients on Chronic Hemodialysis
    Sakakibara, Takashi
    Ishii, Hideki
    Toriyama, Takanobu
    Aoyama, Toru
    Takahashi, Hiroshi
    Kamoi, Daisuke
    Kawamura, Yoshihiro
    Kawashima, Kazuhiro
    Yoneda, Kohei
    Amano, Tetsuya
    Tanaka, Miho
    Yoshikawa, Daiji
    Hayashi, Mutsuharu
    Matsubara, Tatsuaki
    Murohara, Toyoaki
    [J]. CIRCULATION JOURNAL, 2012, 76 (02) : 351 - 355
  • [3] Stent Fracture after Everolimus-Eluting Stent Implantation
    Almasood, Ali S.
    Freixa, Xavier
    Khan, Sohail Q.
    Seidelin, Peter H.
    Dzavik, Vladimir
    [J]. CARDIOLOGY RESEARCH AND PRACTICE, 2011, 2011
  • [4] Everolimus-Eluting Versus Biolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus
    Gyldenkerne, Christine
    Olesen, Kevin K. W.
    Jensen, Lisette O.
    Junker, Anders
    Veien, Karsten T.
    Terkelsen, Christian J.
    Kristensen, Steen D.
    Thim, Troels
    Jensen, Svend E.
    Raungaard, Bent
    Aaroe, Jens
    Kahlert, Johnny
    Villadsen, Anton B.
    Botker, Hans Erik
    Christiansen, Evald H.
    Maeng, Michael
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2019, 124 (05): : 671 - 677
  • [5] Poor Progression of in-Stent Neoatherosclerosis in Patients With Everolimus-Eluting Stent Implantation: Coronary Angioscopic Observation
    Ichikawa, Minoru
    Yoshima, Shohei
    Takei, Yoshizumi
    Kawai, Kenji
    Oshita, Takeshi
    Fukuda, Kenji
    Takagi, Takashi
    Kijima, Yoshiyuki
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2014, 34
  • [6] The Real World Experience of the Everolimus-Eluting Coronary Stent System: Audit of Everolimus-Eluting Coronary Stents
    Aldous, Sally
    Smyth, David
    Blake, James
    McClean, Dougal
    Elliott, John
    [J]. JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2011, 24 (03) : 241 - 246
  • [7] Xience V™ everolimus-eluting coronary stent
    Kukreja, Neville
    Onuma, Yoshinobu
    Serruys, Patrick W.
    [J]. EXPERT REVIEW OF MEDICAL DEVICES, 2009, 6 (03) : 219 - 229
  • [8] The comparison of usefulness of bioresorbable polymer-everolimus eluting stent with platinum chromium-everolimus eluting stent and everolimus-eluting stent in patients with the end-stage chronic kidney disease including hemodialysis
    Sato, Takao
    Kishi, Shohei
    Hatada, Katsuharu
    Okabe, Masaaki
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (18) : B199 - B200
  • [9] Comparison of platinum chromium everolimus-eluting stent with cobalt chromium everolimus-eluting stent in unselected patients undergoing percutaneous coronary intervention
    Li, R. -G.
    Lee, C. -H.
    Low, A.
    Chan, M.
    Chan, K. H.
    Richards, A. M.
    Qu, X. -K.
    Fang, W. -Y.
    Tan, H. C.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2015, 19 (12) : 2213 - 2220
  • [10] Acute stent recoil of bioabsorbable everolimus-eluting coronary stent and everolimus-eluting coronary metal stent: Insight from the ABSORB and SPIRIT trials
    Tanimoto, Shuzou
    Serruys, Patrick W.
    Thuesen, Leif
    Dariusz, Dudek
    de Bruyne, Bernald
    Chevalier, Bernard
    Ormiston, John A.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 23B - 23B